Session Descriptions
Thursday, March 26, 2020
Biology Drives the Surgical and Medical Management of Desmoids
The surgical treatment paradigm for the management of Desmoids is changing and the “wait-and-see” approach is being adopted. This biology of sporadic, “wild type” Desmoids and those associated with germline mutations will be discussed in context of the changing treatment approaches and the newest systemic therapy options.
Management of Breast Cancer in Women Age 70+
This session covers several topics including when to use chemotherapy, the role of anti-HER2 therapy without chemotherapy, adherence to endocrine therapy and the impact of this on the decision to avoid radiation therapy.
The Role of the Surgical Oncologist in Locally Advanced and Metastatic Melanoma
As systemic therapy for advanced melanoma has improved, the role of the surgical oncologist in multidisciplinary management is evolving. This session will present scenarios to consider for utilizing neoadjuvant immunotherapy, summarize the current management recommendations for in-transit melanoma and the new and upcoming systemic agents for the treatment of melanoma. It will also review the role of infusion and perfusion in the management of recurrent and metastatic melanoma.
Practice-Changing Studies of 2019 (Breast, Melanoma, Sarcoma, Endocrine)
Adoption of treatments and techniques that are proven to enhance patient care is imperative in daily practice. Keeping up with the rate of information that is available can be challenging. This forum covers the most significant advances in a variety of diseases including breast, melanoma, sarcoma and endocrine, including neuroendocrine and Merkel Cell.
Updates on IPMN Management
IPMNs are increasingly encountered by the practicing surgeon and guidelines on their management are evolving. This session will review the guidelines on surgical resection versus surveillance of IPMN. It will also cover the role and limitations of EUS in the diagnostic workup on IPMN, disease surveillance strategy, including imaging modality method and examine the role of syst fluid analysis in the identification of high-risk lesions.
Perioperative Opioids in Surgical Oncology for Patients: Call for Action
An increasing body of surgical literature has shown the contribution of perioperative opioid prescriptions on the national opioid epidemic. This session will describe the role that surgeons can play in mitigating the epidemic and summarize four pillars of perioperative opioid reduction programs and cover targeted opioid reduction interventions.
Regional Liver Therapy for Solid Tumor Liver Metastasis
Solid tumor liver metastases are increasingly encountered, and several regional modalities are available including hepatic arterial infusion therapy, Yittrium 90 and transarterial chemoembolization. This session will summarize the evidence behind these therapies, identify the role of different regional liver therapies for various solid tumor liver metastasis and examine the efficacy of these modalities compared to systemic chemotherapy.
Updates in Management of Localized Melanoma
Dramatic changes in the treatment of localized and regional melanoma has led to the use of molecular markers for predictive value and SLND selection, large, multi-center studies have changed the management of nodal basins and the use of imaging in surveillance has become standard. While these approaches are available, they are not all widespread. This session will address the uses of and candidates for molecular markers, review current nodal basin treatment and discuss techniques and uses of surveillance imaging.
New Techniques for Cytoreduction and Peritoneal Chemotherapy for Colorectal Cancer: “How I Do It”
The utilization of cytoreduction and intraperitoneal chemotherapy for gastrointestinal malignancies is growing at high-volume centers. This session will cover the benefits of laparoscopic cytoreduction and HIPEC compared to open techniques and discuss associated key equipment and intraoperative maneuvers. The physiology and mechanics behind pressurized aerosol chemotherapy will also be discussed.
Friday, March 27, 2020
Integrating Theragnostic Principles into Surgical Therapy of Differentiated Thyroid Cancer
Molecular characterization of differentiated thyroid cancer is emerging as a powerful theragnostic tool for guiding specific surgical approach, including the extent of initial surgery, sampling of lymph nodes and postoperative follow-up. This session covers several topics including: selecting the most appropriate molecular pathology tests for tumor characterization, identifying the subgroup of patients based on molecular pathology results for lobectomy versus thyroidectomy for lymph node dissection extent, identifying appropriate indications for molecular radioactive iodine imaging with fusion to anatomic CT.
Practice-Changing Studies of 2019 (HPB, Colorectal and GI)
As the field of surgical oncology evolves and grows in complexity, staying up-to-date on recent advances can be challenging. This session will cover new therapeutics, practice-changing clinical trials and the impact on clinical practice. Four presentations on data quality, upper GI, lower GI and HPB will be covered.
Great Debate: All Women Undergoing Immediate Reconstruction Should Undergo Nipple Sparing Mastectomy
Nipple sparing mastectomy is a newer approach to mastectomy for women undergoing mastectomy with immediate reconstruction. Use of nipple sparing mastectomy varies across practices. This Great Debate will take on the issue including the role of nipple sparing mastectomy, when it is indicated, and which women will benefit from this approach.
Tailoring Breast Cancer Surgery/Management to Patient and Tumor Factors
Breast cancer management occurs at the intersection of the surgical management of the breast and axilla, radiation therapy and systemic therapy. This session examines scenarios that take into account these factors to tailor disease management to patient and tumor factors.
Controversies in Management of Primary and Metastatic Small Bowel Neuroendocrine Tumors
There have been numerous recent advances in diagnosis and treatment of NETs as a whole, including the use of long-acting somatostatin analogue therapy, convention chemotherapy and radiolabeled-somatostatin analogs, all of which have shown improvement in progress-free survival. This session will cover topics where these is no clear consensus regarding management of MNETs including understanding approaches for resectable and unresectable disease, identification of non-surgical treatment options and recognizing key factors in pre- and post-operative management.